000119415 001__ 119415
000119415 005__ 20240228134940.0
000119415 0247_ $$2doi$$a10.1007/s00259-013-2660-z
000119415 0247_ $$2pmid$$apmid:24352789
000119415 0247_ $$2ISSN$$a0340-6997
000119415 0247_ $$2ISSN$$a1432-105X
000119415 0247_ $$2ISSN$$a1619-7070
000119415 0247_ $$2ISSN$$a1619-7089
000119415 0247_ $$2altmetric$$aaltmetric:2316185
000119415 037__ $$aDKFZ-2017-00157
000119415 041__ $$aeng
000119415 082__ $$a610
000119415 1001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b0$$eFirst author$$udkfz
000119415 245__ $$aComparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
000119415 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2014
000119415 3367_ $$2DRIVER$$aarticle
000119415 3367_ $$2DataCite$$aOutput Types/Journal article
000119415 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1487772863_1764
000119415 3367_ $$2BibTeX$$aARTICLE
000119415 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119415 3367_ $$00$$2EndNote$$aJournal Article
000119415 520__ $$a(68)Ga-labelled HBED-CC-PSMA is a highly promising tracer for imaging recurrent prostate cancer (PCa). The intention of this study was to evaluate the feasibility of PET/MRI with this tracer.Twenty patients underwent PET/CT 1 h after injection of the (68)Ga-PSMA ligand followed by PET/MRI 3 h after injection. Data from the two investigations were first analysed separately and then compared with respect to tumour detection rate and radiotracer uptake in various tissues. To evaluate the quantification accuracy of the PET/MRI system, differences in SUVs between PET/CT and corresponding PET/MRI were compared with differences in SUVs between PET/CT 1 h and 3 h after injection in another patient cohort. This cohort was investigated using the same PET/CT system.With PET/MRI, different diagnostic sequences, higher contrast of lesions and higher resolution of MRI enabled a subjectively easier evaluation of the images. In addition, four unclear findings on PET/CT could be clarified as characteristic of PCa metastases by PET/MRI. However, in PET images of the PET/MRI, a reduced signal was observed at the level of the kidneys (in 11 patients) and around the urinary bladder (in 15 patients). This led to reduced SUVs in six lesions. SUVmean values provided by the PET/MRI system were different in muscles, blood pool, liver and spleen.PCa was detected more easily and more accurately with Ga-PSMA PET/MRI than with PET/CT and with lower radiation exposure. Consequently, this new technique could clarify unclear findings on PET/CT. However, scatter correction was challenging when the specific (68)Ga-PSMA ligand was used. Moreover, direct comparison of SUVs from PET/CT and PET/MR needs to be conducted carefully.
000119415 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000119415 588__ $$aDataset connected to CrossRef, PubMed,
000119415 650_7 $$2NLM Chemicals$$aGlu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
000119415 650_7 $$2NLM Chemicals$$aOligopeptides
000119415 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000119415 650_7 $$09G34HU7RV0$$2NLM Chemicals$$aEdetic Acid
000119415 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b1$$udkfz
000119415 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b2$$udkfz
000119415 7001_ $$0P:(DE-HGF)0$$aFenchel, M.$$b3
000119415 7001_ $$0P:(DE-He78)331382460d902d1341dc73db8b990f97$$aEder, Matthias$$b4$$udkfz
000119415 7001_ $$0P:(DE-HGF)0$$aEisenhut, M.$$b5
000119415 7001_ $$aHadaschik, B. A.$$b6
000119415 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b7$$udkfz
000119415 7001_ $$0P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aRöthke, Matthias$$b8$$eLast author$$udkfz
000119415 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-013-2660-z$$gVol. 41, no. 5, p. 887 - 897$$n5$$p887 - 897$$tEuropean journal of nuclear medicine and molecular imaging$$v41$$x1619-7089$$y2014
000119415 909CO $$ooai:inrepo02.dkfz.de:119415$$pVDB
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)331382460d902d1341dc73db8b990f97$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000119415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d11afed6b72f876ad1bba9418e30dac$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000119415 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000119415 9141_ $$y2014
000119415 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119415 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119415 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119415 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119415 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119415 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000119415 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119415 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119415 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119415 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119415 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119415 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119415 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000119415 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000119415 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x1
000119415 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x2
000119415 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000119415 980__ $$ajournal
000119415 980__ $$aVDB
000119415 980__ $$aI:(DE-He78)E060-20160331
000119415 980__ $$aI:(DE-He78)E010-20160331
000119415 980__ $$aI:(DE-He78)E030-20160331
000119415 980__ $$aI:(DE-He78)C060-20160331
000119415 980__ $$aUNRESTRICTED